Nahdi NA, Jo-Ann F, Greanya ED, Jo-Ann H, Tse I, Steinbrecher UP, Erb SR, Yoshida EM

Language: English
References: 21
Page: 156-160
PDF size: 84.09 Kb.

ABSTRACT

Fibrosing cholestatic hepatitis (FCH) is a less common but well-recognized severe complication of recurrent hepatitis C virus (HCV) infection post-liver transplant. This condition is fatal without successful treatment and to date; post-transplant antiviral interferon-based antiviral therapy has been associated with guarded success. The new era of protease inhibitors in the treatment of chronic HCV infection may alter the dismal outcome of this condition. To date, however, the experience with protease inhibitors in this condition is unreported. We report a post-liver transplant recipient with HCV associated FCH treated successfully with boceprevir, peginteferon and ribavirin for severe FCH. The patient was young woman who was a null responder pre-transplant to peginterferon and ribavirin. The peak serum bilirubin 391 µmol/L normalized to 15 µmol/L by week 8 of therapy. The pre-treatment HCV viral load of › 78 million IU/mL, decreased to 78 IU/mL at week 8 of therapy and was undetectable by week 12 and at the end of 48 week of treatment. 12 weeks post treatment, the HCV viral load remains undetectable. Significant anemia and neutropenia were encountered. Tacrolimus dosage titrated to trough levels, required marked reduction to 0.5 mg three times weekly. Despite the suboptimal peginterferon and ribavirin dosing, limited by adverse effects, full boceprevir dosing was maintained, with resolution of liver dysfunction. Boceprevir was obtained on compassionate grounds from the manufacturer before its licensure in Canada and this was the first use of boceprevir in the world for post-transplant FCH.

REFERENCES

1. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.

2. Furuta K, Takahashi T, Aso K, Hoshino H, Sato K, Kakita A. Fibrosing cholestatic hepatitis in a live transplant recipient with hepatitis C virus infection: a case report. Transplant Proc 2003; 35: 389-91.

3. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219.

4. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342: 1175.

5. Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol 2007; 6: 186-9.

6. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphmamide/rituximab for low grade non-Hodgkin’s lymphoma. Eur J Med Res 2008; 13: 483-6.

7. Lisa RD, James MC. Early histologic changes in Fibrosing cholestatic hepatits C. Liver Transpl 2007; 13: 219-26.

8. Davies SE, Portmann BC, O’Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological finding after transplantation for chronic hepatitis B infection, including a unique pattern of Fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.

9. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.

10. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-20.

11. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202- 10.

12. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-anaylsis. Liver Transpl 2007; 13: 21-9.

13. Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, et al. Successful treatment of Fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011; 43: 905-8.

14. Bolkhir A, Brunt EM, Solomon HS, Hayashi PH. Sustained resolution of Fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007; 13: 309-11.

15. Incivek (Telaprevir) (package insert). Cambridge, Mass: Vertex Pharmaceuticals; 2011.

16. Victrelis (boceprevir) (package insert). Whitehouse Station, NJ: Merck&Co; 2011.

17. Bacon BR, Gordon SC, Lawitz E, Marcellin P, et al. Boceprevir for previously treated chronic HCV genotype1 infection. N Engl J Med 2011; 364: 1207-17.

18. Vierling J, Flamm S, Gordon S, Lawitz E, Bronowicki JP, Davis M, Yoshida E, et al. Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavrin: the PROVIDE Study. Hepatology 2011; 54(Suppl.): 796-77A (Abstract).

19. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18.

20. Wilby KJ, Greanya E, Ford JE, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 197-85.

21. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic hepatitis C genotype 1 infection. N Engl J Med 2011; 364: 1195-20.